BioMarin Pharmaceutical’s (BMRN) “Sector Perform” Rating Reiterated at Royal Bank Of Canada

BioMarin Pharmaceutical (NASDAQ:BMRN)‘s stock had its “sector perform” rating reiterated by stock analysts at Royal Bank Of Canada in a report released on Tuesday,Benzinga reports. They currently have a $66.00 price objective on the biotechnology company’s stock. Royal Bank Of Canada’s price target would suggest a potential upside of 20.99% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Guggenheim lowered their target price on shares of BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Sanford C. Bernstein boosted their target price on shares of BioMarin Pharmaceutical from $90.00 to $94.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Wells Fargo & Company increased their target price on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Barclays lifted their price target on shares of BioMarin Pharmaceutical from $80.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, March 3rd. Finally, Loop Capital set a $105.00 price target on BioMarin Pharmaceutical in a report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $90.91.

BioMarin Pharmaceutical Trading Down 1.6%

BMRN traded down $0.91 during trading on Tuesday, reaching $54.55. 991,271 shares of the stock traded hands, compared to its average volume of 1,999,276. The company has a quick ratio of 3.50, a current ratio of 5.21 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $10.54 billion, a PE ratio of 30.58, a P/E/G ratio of 0.54 and a beta of 0.23. The stock’s 50-day moving average is $56.93 and its 200 day moving average is $56.32. BioMarin Pharmaceutical has a 12 month low of $50.76 and a 12 month high of $66.28.

Insider Transactions at BioMarin Pharmaceutical

In other news, EVP Charles Greg Guyer sold 16,486 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the transaction, the executive vice president directly owned 79,953 shares of the company’s stock, valued at approximately $4,833,958.38. The trade was a 17.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregory R. Friberg sold 6,326 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total value of $381,963.88. Following the transaction, the executive vice president directly owned 37,578 shares of the company’s stock, valued at approximately $2,268,959.64. This represents a 14.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On BioMarin Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BMRN. CIBC Private Wealth Group LLC increased its stake in BioMarin Pharmaceutical by 38.2% in the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 179 shares during the last quarter. Northwestern Mutual Investment Management Company LLC increased its stake in BioMarin Pharmaceutical by 0.4% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock valued at $2,554,000 after purchasing an additional 183 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in BioMarin Pharmaceutical by 7.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 195 shares during the last quarter. Grandfield & Dodd LLC boosted its stake in BioMarin Pharmaceutical by 1.2% in the third quarter. Grandfield & Dodd LLC now owns 18,967 shares of the biotechnology company’s stock valued at $1,027,000 after acquiring an additional 217 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in BioMarin Pharmaceutical by 3.4% in the third quarter. EverSource Wealth Advisors LLC now owns 7,151 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 235 shares in the last quarter. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Company raised FY-2026 revenue guidance to $3.825–$3.925 billion (midpoint implies ~20% Y/Y growth) and cited recent additions (GALAFOLD®, POMBILITI® + OPFOLDA®) as drivers — a material top-line upgrade that supports longer-term growth expectations. Read More.
• Positive Sentiment: Q1 revenue beat consensus: $766.21M vs. ~$752M consensus, showing organic revenue growth despite the EPS miss. This revenue strength helps justify the raised guidance. Read More.
• Positive Sentiment: Broker consensus remains constructive overall — the stock carries an average “Moderate Buy” from analysts, which cushions downside risk from a single-quarter miss. Read More.
• Neutral Sentiment: Full Q1 2026 earnings call transcript and the investor presentation are available for details on product trends, margin drivers and pipeline commentary — useful for parsing management’s tone on sustainment of revenue growth. Read More. • Read More.
• Negative Sentiment: Q1 EPS missed Street estimates: $0.76 vs. $0.94 consensus (down from $0.95 a year ago), and reported EPS missed both Zacks and other consensus figures — an immediate catalyst for selling pressure. Read More. • Read More.
• Negative Sentiment: HC Wainwright reaffirmed a “neutral” rating with a $55 price target (~slight downside to recent levels), signaling limited near-term upside from the analyst community despite the revenue beat. Read More.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.